[Intensive care treatment for neuroleptic malignant syndrome].
We report a case of severe neuroleptic malignant syndrome developing in a 28-year-old female patient following deliberate self-poisoning with atypical antipsychotic drugs and serotonin reuptake inhibitors. Because of an increasing loss of consciousness she was rapidly transferred to an Intensive Care Unit. Following this, she became progressively febrile associated with rhabdomyolysis and life-threatening organ dysfunctions. Due to fast diagnosis and immediate therapy the patient was treated successfully. This article describes etiology, pathophysiology and symptoms of neuroleptic malignant syndrome. In addition therapeutic options are discussed.
Hensel
Mario
M
Abteilung für Anästhesiologieund Intensivmedizin, Park-Klinik Weissensee, Berlin. hensel@park-klinik.com
Böhler
Klaus
K
Marnitz
Rudolf
R
Binder
Christian
C
von Brevern
Michael
M
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy; D003128:Coma / Q000139:chemically induced; D003402:Creatine Kinase / Q000097:blood; D003422:Critical Care; D003620:Dantrolene / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009211:Myoglobin / Q000097:blood; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D000077152:Olanzapine; D020280:Sertraline / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D009125:Muscle Relaxants, Central; D009211:Myoglobin; D001569:Benzodiazepines; D003402:Creatine Kinase; D003620:Dantrolene; D000077152:Olanzapine; D020280:Sertraline